Tacrolimus and Cyclosporin Pharmacotherapy, Detection Methods, Cytochrome P450 Enzymes after Heart Transplantation
CONCLUSION: Polypharmacy based on tacrolimus or cyclosporine needs vigilant therapeutic drug monitoring due to the cytochrome P450 enzymes associated with biochemical variables in metabolic pathways. Further attention to polypharmacy should be given to circulate drugs that could hide pharmacokinetics interactions associated with infections, malignancies, chronic kidney disease, and rejection after organ transplantation.PMID:37496131 | DOI:10.2174/1871525721666230726150021
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Authors: Zahra Tolou-Ghamari Source Type: research
More News: Brain | Cancer & Oncology | Cardiology | Cardiovascular | Celexa | Chemistry | Cholesterol | Chronic Kidney Disease | Citalopram | Clopidogrel | Clotrimazole | Diltiazem | Fluconazole | Fluvastatin | Heart | Heart Transplant | Hematology | Ketoconazole | Kidney Transplant | Kidney Transplantation | Neurology | Neuroscience | Phenytoin | Plavix | Pravastatin | Prograf | Restasis | Science | Sertraline | Statin Therapy | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology | Verapamil | Zoloft